PKI-166

• Description:

  PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 0.7 nM[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H301

• Target:

  EGFR

• Type:

  Reference compound

• Related Pathways:

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pki-166.html

• Purity:

  98.92

• Solubility:

  DMSO : ≥ 125 mg/mL

• Smiles:

  OC1=CC=C (C2=CC3=C (N=CN=C3N2) N[C@@H] (C4=CC=CC=C4) C) C=C1

• Molecular Formula:

  C20H18N4O

• Molecular Weight:

  330.38

• Precautions:

  H301

• References & Citations:

  [1]Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000 Jun 1;60 (11) :2926-35.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  187724-61-4